Fractures in women treated with raloxifene or alendronate: a retrospective database analysis

[1] Riggs BL(1995)The worldwide problem of osteoporosis: insights afforded by epidemiology Bone 17 505S-511S

[2] Melton LJ(2008)FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-397

[3] Kanis JA(2007)Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025 J Bone Miner Res 22 465-475

[4] Johnell O(1996)Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535-1541

[5] Oden A(1998)Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077-2082

[6] Johansson H(1999)Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis JAMA 282 637-645

[7] McCloskey E(2002)The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation J Clin Endocrinol Metab 87 985-992

[8] Burge R(1999)Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation JAMA 281 2189-2197

[9] Dawson-Hughes B(2001)Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass Breast Cancer Res Treat 65 125-134

[10] Solomon DH(2007)Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures Bone 40 843-851

[1] Riggs BL(1995)The worldwide problem of osteoporosis: insights afforded by epidemiology Bone 17 505S-511S

[2] Melton LJ(2008)FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385-397

[3] Kanis JA(2007)Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025 J Bone Miner Res 22 465-475

[4] Johnell O(1996)Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535-1541

[5] Oden A(1998)Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 2077-2082

[6] Johansson H(1999)Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis JAMA 282 637-645

[7] McCloskey E(2002)The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation J Clin Endocrinol Metab 87 985-992

[8] Burge R(1999)Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation JAMA 281 2189-2197

[9] Dawson-Hughes B(2001)Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass Breast Cancer Res Treat 65 125-134

[10] Solomon DH(2007)Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures Bone 40 843-851